|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
RS Stein, JM Flexner and SE Graber
Twenty-seven patients receiving a standard cytosine arabinoside and
daunorubicin regimen as induction of reinduction therapy of acute
myelogenous leukemia were randomly assigned to receive lithium carbonate,
300 mg t.i.d., or no lithium. Treatment groups were comparable with respect
to age and baseline granulocyte counts. All patients developed granulocyte
nadirs below 100/cu mm. By actuarial analysis, the median duration of
granulocytopenia, less than 1000/cu mm, was 16.0 days in the lithium group
and 24.6 days in the no-lithium group, p = 0.013. The median duration of
granulocytes less than 500/cu mm also favored the lithium group but only
approached statistical significance: 14.0 days versus 20.5 days, p = 0.054.
Lithium levels between 0.5 and 1.0 meq/liter were easily maintained in 11
of 12 patients receiving lithium, 300 mg t.i.d., and toxicity directly
attributable to lithium was not observed. Despite the shortened duration of
neutropenia, the incidence of infections and the rate of remission were not
affected.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1979 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
